Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 6, 2022; 10(13): 4161-4170
Published online May 6, 2022. doi: 10.12998/wjcc.v10.i13.4161
Primary myelofibrosis with thrombophilia as first symptom combined with thalassemia and Gilbert syndrome: A case report
Guzailinuer Wufuer, Kaisaer Wufuer, Tu Ba, Tao Cui, Ling Tao, Ling Fu, Ming Mao, Ming-Hui Duan
Guzailinuer Wufuer, Ling Tao, Ling Fu, Ming Mao, Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, Xinjiang Uygur Autonomous Region, China
Kaisaer Wufuer, Department of Thoracic Surgery, The Eighth Affiliated Hospital of Xinjiang Medical University, Urumqi 830001, Xinjiang Uygur Autonomous Region, China
Tu Ba, Department of Pathology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, Xinjiang Uygur Autonomous Region, China
Tao Cui, Department of Radiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, Xinjiang Uygur Autonomous Region, China
Ming-Hui Duan, Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, China
Author contributions: Wufuer G, Wufuer K, Ba T, Cui T, and Tao L contributed equally to this work; Fu L and Mao M designed the research study; Duan MH analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: Wufuer G has received fees for serving as a speaker, an Associate Chief Physician at People's Hospital of Xinjiang Uygur Autonomous Region; Duan MH has received research funding from Peking Union Medical College Hospital.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Hui Duan, MD, Doctor, Department of Hematology, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. mhduan@sina.com
Received: August 11, 2021
Peer-review started: August 11, 2021
First decision: September 2, 2021
Revised: September 17, 2021
Accepted: March 14, 2022
Article in press: March 14, 2022
Published online: May 6, 2022
Abstract
BACKGROUND

A 46-year-old Han man first had sigmoid sinus and transverse sinus venous thrombosis at the age of 42. At the age of 44, he once again developed thrombosis. Genetic testing showed heterozygous SERPINC1 mutation, bone marrow biopsy showed fibrosis grade 1 (MF-1), and JAK2 V617F mutation was positive, accompanied by UGT1A1 mutation and β-thalassemia gene mutation.

CASE SUMMARY

A 46-year-old Han man was first found to have sigmoid sinus and transverse sinus venous thrombosis at the age of 42 but had no individual or family thrombosis history, and he had been regularly taking warfarin anticoagulant therapy for a long period of time. At the age of 44, venous thrombosis reappeared in parts of the intrahepatic vein, main portal vein, splenic vein, and superior mesenteric vein, and his spleen was obviously enlarged. He had a history of jaundice for many years, and genetic testing revealed that he carried a heterozygous SERPINC1 mutation. Bone marrow biopsy showed multifocal fibrous tissue hyperplasia among trabeculae and focal fibrosis. He was positive for the JAK2 V617F mutation. At the same time, UGT1A1 and β-thalassemia gene mutations existed, and a SERPINC1 mutation and UGT1A1 mutation were both found in his parents.

CONCLUSION

The patient in this case had thrombophilia as the primary symptom, JAK2V617-positive myeloproliferative neoplasm (MPN) was the main potential cause, and hereditary AT-III deficiency may have been one of multiple secondary causes. It remains to be determined whether UGT1A1 and β-thalassemia gene mutations are related to thrombophilia. However, the clinical features of MPN in this patient were hidden, and the relevant clinical features of coexisting thalassemia and hereditary Gilbert syndrome, reported here for the first time domestically and abroad, were complicating factors, causing great difficulties for a clear diagnosis. Thus, when thrombophilia has been determined, it is necessary to screen the relevant latent problems overall. When the clinical features cannot be perfectly explained by one etiology, a relevant comprehensive examination should also be initiated from the perspective of multiple etiologies.

Keywords: Thrombophilia, Prefibrotic myelofibrosis, Negative family thrombosis history, Case report

Core Tip: Thrombophilia is genetic or acquired defect, or there are acquired risk factors and a high thromboembolic tendency. Hereditary antithrombin (AT) deficiency is a genetic defect caused by a mutation in the AT coding gene SERPINCI1, which is one of the major risk factors for hereditary thrombophilia. We report a case of thrombotic disorder with hereditary AT deficiency, in which genetic tests revealed a heterozygous SERPINC1 mutation, and a JAK2V617-positive myeloproliferative neoplasm was a potential acquisition factor for venous thrombosis. At the same time, this patient was genetically confirmed to have both UGT1A1 and β-thalassemia gene mutations. In clinical work, under the premise of clear thrombophilia, comprehensive screening of relevant occult factors is necessary.